

DAFTAR PUSTAKA

- Achilles N., Mosges R., dkk. 2013. *Nasal saline irrigations for the symptoms of acute and chronic rhinosinusitis. Current allergy and asthma reports*, 13(2), 229–235.
- Adji, IS. Et al. *Pengaruh heat shock protein-70 (HSP-70) dan heat shock factor-1 (HSF-1) pada polip hidung*. ORLI, 2016.
- Ahern, S., & Cervin, A., dkk. 2019. *Inflammation and Endotyping in Chronic Rhinosinusitis-A Paradigm Shift. Medicina (Kaunas, Lithuania)*, 55(4), 95.
- Amelia, N.L., Zuleika, P., Utama, D.S. 2017. Prevalensi rhinosinusitis kronik di RSUP Dr. Mohammad Hoesin Palembang. *Maj Kedokt Sriwijaya*.
- Basquets J M., Hwang P H., dkk. 2006. *Nonpolypoid Rhinosinusitis: Classification, Diagnosis and Treatment*. Dalam: Bailey B J., and Johnson, J.T., Editors. *Head and Neck Surgery-Otolaryngology*. 4th Edition. Philadelphia: Lippincot Williams & Wilkins. Page: 405-416.
- Bequignon, E., Mangin, D., Becaude, J., Pasquier, J., Angely, C., Bottier, M., et al. 2020. Pathogenesis of chronic rhinosinusitis with nasal polyps: role of IL-6 in airway epithelial cell dysfunction. *J Transl Med*.
- Boek, W. M., Keleş, N., Graamans, K., & Huizing, E. H. 1999. *Physiologic and hypertonic saline solutions impair ciliary activity in vitro. The Laryngoscope*, 109(3), 396–399.
- Chang, O.L., Maze, M. 2022. Defining the role of interleukin-6 for the development of perioperative neurocognitive disorders: evidence from clinical and preclinical studies. *Front Aging Neurosci*. Available from URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908597/>
- Cwiklinska H. et al. The Heat Shock Protein HSP70 Promotes Th17 Genes' Expression via Specific Regulation of microRNA. *Int. J. Mol. Sci*. 2020, 21, 2823
- ir S Sethi., dkk. *Practical Rhinology: Applied Surgical Anatomy of the Nasal Cavity and Paranasal Sinus*. First Published in Great Britain. London 2010. Page: 1-14



- Fagotti, A., Lucentini, L., Simoncelli, F., Porta, G.L., Brustenga, L., Bizzarri, I., et al. 2022. HSP70 upregulation in nasal mucosa of symptomatic children with allergic rhinitis and potential risk of asthma development. *Sci Rep*
- Ference, E.H., Tan, B.K., Hulse, K.E., Chandra, R.K., Smith, S.B., Kern, R.C., et al. 2015. Commentary on gender differences in prevalence, treatment, and quality of life of patients with chronic rhinosinusitis. *Summer*;6(2)
- Fokkens W, Lund V, Mullol J, et al. European position paper on rhinosinusitis and nasal polyps. *Rhinology*, 2007; 45(suppl 20): 1-139.
- Fokkens WJ. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. *Rhinology Supplement* 29: 1 - 464, 2020
- Garavello, W., Romagnoli, M., Sordo, L., Gaini, R. M., dkk. 2003. *Hypersaline nasal irrigation in children with symptomatic seasonal allergic rhinitis: a randomized study. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*, 14(2), 140–143
- Hauptman, G., & Ryan, M. W. 2007. *The effect of saline solutions on nasal patency and mucociliary clearance in rhinosinusitis patients. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*, 137(5), 815–821.
- Heatley D G., McConnell K E., Kille T L., Levenson G I., dkk. 2010. *Nasal Irrigations for The Allevation of Sinonasal Symptoms. Otolaryngology Head and Neck Surgery*. Hh. 125(1): 44-48.
- Hoehle, I.P., Philips, K.M., Caradonna, D.S., Gray, S.TT., Sedaghat, A.R. 2017. A contemporary analysis of clinical and demographic factors of chronic rhinosinusitis patients and their association with disease severity. *Ir J Med Sci*.
- S. et al. *Management of rhinosinusitis in adults in primary care. Malaysian Family Physicia*, 2018



- Hwang PH., Abdalkhani A., dkk. 2009. Embryologi, Anatomy and Physiology of The Nose and Paranasal Sinuses. In Snow JB, Wackym PA, editors. Ballenger's Otorhinolaryngology Head and neck Surgery. 17th Ed. Connecticut. BC Decker Inc. Page: 455-463.
- Jackman AH, Kennedy DW. *Pathophysiology of sinusitis*. In Brook I, eds. *Sinusitis from microbiology to management*. New York: Taylor & Francis, 2006;109-129.
- Jawa, R.S., Anillo, S., Huntoon, K., Baumann, H., Kulaylay, M. 2018. Interleukin-6 in surgery, trauma and critical care part II: clinical implications. J Intensive Care Med. Available from URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223019/>
- Johnson J T., Rosen C A., dkk. 2014. Editors. Bailey's Head and Neck Surgery Otolaryngology. 5th Edition. Vol. 1. Philadelphia: Lippincot Williams & Wilkins. Page: 535-549.
- Kentjono, W., 2004. Rinosinusitis: etiologi dan patofisiologi. In eds.. In: *Naskah lengkap perkembangan terkini diagnosis dan penatalaksanaan rinosinusitis*. Surabaya: Dep./SMF THT-KL Univ.Airlangga, pp. 1-16.
- Kim C. H., Song M. H., Young E.A., Lee J. G., Yoon J. H., dkk. 2005. Effect of Hypo-Iso and Hypertonic Saline Irrigation on Secretory Mucins and Morphology of Cultured Human Nasal Epthelial Cells. Acta Otolaryngol. Hh. 125: 1296-1300.
- Kimura, F., Itoh, H., Ambiru, S., Shimizu, H., Togawa, A., Yoshidome, H., et al. 2004. Circulating heat-shock protein 70 is associated with postoperative infection and organ dysfunction after liver resection. Am J Surg.
- Kubota, K., Takeno, S., Taruya, T., Sasaki, A., Ishino, T., Hirakawa, K. 2017. IL-5 and IL-6 are increased in the frontal recess of eosinophilic chronic rhinosinusitis patients. J Otolaryngol.
- Kusnanti, C., Ratnawati, LM. *Distribusi penderita rinosinusitis kronis yang menjalani pembedahan di RSUP Sanglah Denpasar*. Medicina, 2019.



- Kwon E, O'Rourke MC. *Chronic Sinusitis*. NCBI, 2020.
- Lalwani AK. 2007. *Current Diagnosis and Treatment: Otolaryngology Head and Neck Surgery*. 2nd Ed. USA: McGraw Hill.
- Leung RM., Walsh WE., Kern RC., dkk. 2014. *Sinonasal Anatomy and Physiology*. In: Jhonson JT., Rosen CA., editors. *Bailey's Head and Neck Surgery Otolaryngology*. 5th Ed. Philadelphia, Lippincot Williams & Wilkins. Page: 359-369.
- Levina H., Clemente MP., dkk. 2005. *Surgical Anatomy of The Paranasal Sinus in: Sinus Surgery Endoscopic an Microscopic Approaches*. Thieme Medical Publishers. New York. Page: 10-25.
- Lindquist S., Craig E A., dkk. 1998. *The Heat-Shock Proteins. Annual Review of Genetics*, 22(1), 631–677.
- Longbottom, E.R., Torrance, H.D., Owen, H.C., Fragkou, P.C., Hinds, C.J., Pearse, R.M, et al. 2019. Features of post-operative immune suppression are reversible with interferon gamma and independent of IL-6 pathways.
- Maharani, I., Wijaya, J.H. 2023. Chronic rhinosinusitis epidemiology study in those who need a surgical intervention at Saiful Anwar General Hospital Ward January 1st,2018-December 31th 2021. *EJENTAS*
- Mangunkusumo E., Soetjipto D., dkk. 2012. *Sinusitis. Buku Ajar Ilmu Kesehatan Telinga Hidung dan Tenggorok Bedah Kepala Leher*. Edisi dua belas. 150-154. Balai Penerbit Fakultas Kedokteran Universitas Indonesia. Jakarta. 2012.
- Marlina, L., Ratananda, S.S., Madiadipoera, T. 2020. Impact of pharmacotherapy to decrease interleukin-6 in patients with chronic rhinosinusitis without nasal polyp. *ORLI*;50(1)
- McCormick SM. Heller NM. Commentary: IL-4 And IL-13 Receptors And Signaling. *Cytokine*. 2015 September ; 75(1): 38–50.
- Min, HJ. Et al. *HSP70 is associated with the severity of inflammation in chronic rhinosinusitis*. *AJRA*, 2016
- isari, Y., Nuryanti D. 2017. Faktor-faktor prognostic kesembuhan pengobatan medikamentosa rhinosinusitis kronis di poli THT RSUD



- A.Dadi Tjokrodipo Bandar Lampung tahun 2017. J Ilmu Kedokt Kes;3(4)
- Papsin B., McTavish A., dkk. 2003. Saline Nasal Irrigations: Its Role As An Adjunct Treatment. Can Fam Physician, hh. 49. Page: 168-173.
- Pinheiro AD., Facer GW., Kern EB., dkk. Sinusitis: Current Concepts And Management. In: Bryon J-Bailey Head and Neck Surgery-Otolaryngology. Caltrown KH (Gen Ed) 2nd Edition. Philadelphia Lippicont-Raven; 1998. Page: 441-455.
- Probst R. et al. Basic Otorhinolaryngology: A Step-By-Step Learning Guide. Thieme, 2006.
- Rabago D., Zgierska A., dkk. 2009. Saline Nasal Irrigation for Upper Respiratory Conditions. Am Fam Physician, hh. 80(10): 1117-1119.
- Rahmi, A. & Punagi, Q., 2003-2008. *Pola Penyakit sub-Bagian Rinologi di RS Pendidikan Makassar*, Makassar: Bagian Ilmu Kesehatan THTKL, Fakultas Kedokteran Universitas Hasanuddin.
- Ravantara, C.M., Magdi, Y.L., Kasim, B.I. 2019. Prevalence of chronic rhinosinusitis in ENT department RSUP Dr. Mohammad Hoesin Palembang. Sriwijaya J Med
- Shoseyov D., Bibi H., Shai P., Shosayov N., Shazberg G., Hurvitz H., dkk. 1998. Treatment With Hypertonic Saline Versus Normal Saline Nasal Wash of Pediatric Chronic Sinusitis. J Allergic Clin Immunol. Hh.101: 602-605.
- Slovick A., Long J., Hopkins C. 2014. Updates In The Management of Chronic Rhinosinusitis. Clinical Practice. Future Medicine. Page: 649-663.
- Soetjipto D., Wardani., dkk. 2012. Sinus Paranasal. In: Buku Ajar Ilmu Kesehatan Telinga Hidung dan Tenggorok Bedah Kepala Leher. Edisi dua belas. 119-148. Balai Penerbit Fakultas Kedokteran Universitas Indonesia. Jakarta. 2012.



J.N., Castro, F.O., Souza, C.L., Cheikh, M.R., Ramos, H.V., onseca, S.G., et al. 2021. Is there a difference between the reoperative and postoperative serum levels of interleukin-6 and

- tumor necrosis factor- α in children submitted to adenotonsillectomy. *Int Arch Otorhinolaryngol*.
- Stocki P, Dickinson AM. The Immunosuppressive Activity of Heat Shock Protein 70. *Autoimmune Diseases*; Volume 2012.
- Suh JD, Kennedy DW. Treatment Options for Chronic Rhinosinusitis. *Proc Am Thorac Soc Vol 8*. pp 132–140, 2011.
- Tsybikov, NN. Et al. *Heat shock protein 70 and anti-heat shock protein 70 antibodies in nasal secretions of patients with chronic rhinosinusitis*. Oceanside Pub, 2016
- Tylicka M. et al. Intraoperative Peritoneal Interleukin-6 Concentration Changes in Relation to the High-Mobility Group Protein B1 and Heat Shock Protein 70 Levels in Children Undergoing Cholecystectomy. *Mediators of Inflammation*, 2020.
- Ural A., Oktmer T K., Kizil Y., Heri F., Uslu S., dkk. 2009. Impact of Isotonic and Hypertonic Saline Solutions on Mucociliary Activity in Various Nasal Pathologies: Clinical Study. *The Journal of Laryngology & Otology*. Hh. 123: 517-521.
- Wang J. et al. Effects of pepsin A on heat-shock protein 70 response in laryngopharyngeal reflux patients with chronic rhinosinusitis. *Acta Otolaryngol*; 2017, Vol.137(12):1253–1259
- Young L C., Nicholas W S., dkk. 2012. Efficacy of Medical Therapy in Treatment of Chronic Rhinosinusitis, *Allergy Rhinol*. Hh. 3: e8-e12.



LAMPIRAN


Lampiran 1. Cara pengolahan sampel penelitian dengan menggunakan ELISA KIT HSP-70

7. Assay procedure

1. Set standard, test sample and control (zero) wells on the pre-coated plate and record their positions. It is recommended to measure each standard and sample in duplicate. Note: add all solutions to the bottom of the plate wells while avoiding contact with the well walls. Ensure solutions do not foam when adding to the wells.
2. Aliquot 100µl of standard solutions into the standard wells.
3. Add 100µl of Sample / Standard dilution buffer into the control (zero) well.
4. Add 100µl of properly diluted sample (serum, plasma, tissue homogenates and other biological fluids) into test sample wells.
5. Cover the plate with the sealer provided in the kit and incubate for 90 min at 37°C.
6. Aspirate the liquid from each well, do not wash. Immediately add 100µL of Biotinylated Detection Ab working solution to each well. Cover the plate with a plate seal and gently mix. Incubate for 1 hour at 37°C.
7. Aspirate or decant the solution from the plate and add 350µL of wash buffer to each well and incubate for 1-2 minutes at room temperature. Aspirate the solution from each well and clap the plate on absorbent filter paper to dry. Repeat this process 3 times. Note: a microplate washer can be used in this step and other wash steps.
8. Add 100µL of HRP Conjugate working solution to each well. Cover with a plate seal and incubate for 30 min at 37°C.
9. Aspirate or decant the solution from each well. Repeat the wash process for five times as conducted in step 7.
10. Add 90µL of Substrate Reagent to each well. Cover with a new plate seal and incubate for approximately 15 min at 37°C. Protect the plate from light. Note: the reaction time can be shortened or extended according to the actual color change, but not by more than 30min.
11. Add 50 µL of Stop Solution to each well. Note: Adding the stop solution should be done in the same order as the substrate solution.
12. Determine the optical density (OD value) of each well immediately with a microplate reader set at 450 nm.



Lampiran 2. Cara pengolahan sampel penelitian dengan menggunakan ELISA KIT IL 6



Lampiran 3. Hasil pemeriksaan sampel penelitian dengan menggunakan ELISA KIT HSP-70

Test items: HSP 70
Main wavelength: 450
Sub wavelength:
Testing time: 2023-09-18 13:01:08
Review:

Plate No.: 41
cut-off:
Tester: 1000
Report time: 18/09/2023 13:04:59


	1	2	3	4	5	6	7	8	9	10	11	12
Type	STD1	1	9	17	25	33	41	49	57	65	73	81
Result	50,0000	0,4256	4,4543	2,4898	0,3262	0,5186	0,0673	0,0517	0,0166	0,0527	0,0497	0,0599
OD value	1,3939	0,0319	0,2431	0,1504	0,0248	0,0383	-0,0889	-0,0887	-0,0884	-0,0881	-0,0880	-0,0876
Conc	50,0000	0,4256	4,4543	2,4898	0,3262	0,5186	0,0673	0,0517	0,0166	0,0527	0,0497	0,0599
Type	STD2	2	10	18	26	34	42	50	58	66	74	82
Result	25,0000	2,9284	2,3347	2,9305	7,2799	1,2247	0,0397	0,0124	0,0517	0,0486	0,0100	0,0183
OD value	0,9483	0,1722	0,1425	0,1723	0,3603	0,0822	-0,0888	-0,0884	-0,0882	-0,0879	-0,0876	-0,0874
Conc	25,0000	2,9284	2,3347	2,9305	7,2799	1,2247	0,0397	0,0124	0,0517	0,0486	0,0100	0,0183
Type	STD3	3	11	19	27	35	43	51	59	67	75	83
Result	12,5000	10,6802	3,6849	1,4715	2,0099	0,3358	0,0507	0,0219	0,0476	0,0092	0,0069	0,0149
OD value	0,4477	0,4851	0,2082	0,0963	0,1256	0,0255	-0,0887	-0,0884	-0,0881	-0,0879	-0,0877	-0,0874
Conc	12,5000	10,6802	3,6849	1,4715	2,0099	0,3358	0,0507	0,0219	0,0476	0,0092	0,0069	0,0149
Type	STD4	4	12	20	28	36	44	52	60	68	76	84
Result	6,2500	1,7966	1,5719	3,5199	1,6625	0,6483	0,0246	0,0748	0,0727	0,0062	0,0397	0,0497
OD value	0,3816	0,1142	0,1019	0,2005	0,1069	0,0469	-0,0888	-0,0885	-0,0882	-0,0880	-0,0877	-0,0875
Conc	6,2500	1,7966	1,5719	3,5199	1,6625	0,6483	0,0246	0,0748	0,0727	0,0062	0,0397	0,0497
Type	STD5	5	13	21	29	37	45	53	61	69	77	85
Result	3,1300	2,2414	2,3366	1,9345	6,8326	0,3262	0,0348	0,0466	0,0684	0,0781	0,0358	0,0456
OD value	0,1868	0,1377	0,1426	0,1216	0,3427	0,0248	-0,0888	-0,0885	-0,0882	-0,0880	-0,0877	-0,0875
Conc	3,1300	2,2414	2,3366	1,9345	6,8326	0,3262	0,0348	0,0466	0,0684	0,0781	0,0358	0,0456
Type	STD6	6	14	22	30	38	46	54	62	70	78	86
Result	1,5600	3,2431	7,2876	8,3370	2,1874	0,4514	0,0589	0,0579	0,0255	0,0348	0,0310	0,0407
OD value	0,1019	0,1874	0,3606	0,4007	0,1349	0,0337	-0,0886	-0,0883	-0,0880	-0,0878	-0,0876	-0,0873
Conc	1,5600	3,2431	7,2876	8,3370	2,1874	0,4514	0,0589	0,0579	0,0255	0,0348	0,0310	0,0407
Type	STD7	7	15	23	31	39	47	55	63	71	79	87
Result	0,7800	2,7052	1,2991	8,7834	1,1887	0,0705	0,0320	0,0310	0,0210	0,0301	0,0695	0,0792
OD value	0,0522	0,1612	0,0865	0,4173	0,0801	-0,0048	-0,0888	-0,0885	-0,0882	-0,0880	-0,0877	-0,0875
Conc	0,7800	2,7052	1,2991	8,7834	1,1887	0,0705	0,0320	0,0310	0,0210	0,0301	0,0695	0,0792
Type	BLK	8	16	24	32	40	48	56	64	72	80	88
Result	0,0000	9,4248	1,4325	0,8788	1,7596	0,3139	0,0568	0,0077	0,0175	0,0537	0,0641	0,0748
OD value	0,0000	0,4407	0,0941	0,0615	0,1122	0,0239	-0,0888	-0,0885	-0,0882	-0,0880	-0,0877	-0,0875
Conc	0,0000	9,4248	1,4325	0,8788	1,7596	0,3139	0,0568	0,0077	0,0175	0,0537	0,0641	0,0748



Item:HSP 70

Test Time : 18/09/2023 13:01:08

$$y=(4,6891--0,0036)/(1+(X/136,0486)^{-0,8458})+-0,0036 \quad R^2=0,9891$$



Optimized using
trial version
www.balesio.com

Lampiran 4. Hasil pemeriksaan sampel penelitian dengan menggunakan ELISA KIT IL 6

Test items: IL-6 BT Lab

Plate No.: 42

Main wavelength: 450

cut-off:

Sub wavelength:

Tester: 1000

Testing time: 2023-09-18 13:46:01

Report time: 18/09/2023 13:48:25


Review:

	1	2	3	4	5	6	7	8	9	10	11	12
Type	STD1	1	9	17	25	33						
Result	500.0000	0.9431	0.5982	0.2430	0.4706	0.9431						
OD value	1.8563	-0.0274	-0.0109	-0.0197	0.0236	0.0240						
Conc	500.0000	0.9431	0.5982	0.2430	0.4706	0.9431						
Type	STD2	2	10	18	26	34						
Result	250.0000	1.1133	0.7715	0.4224	58.8950	112.2924						
OD value	1.3090	0.0143	0.0248	0.0178	0.4369	0.7335						
Conc	250.0000	1.1133	0.7715	0.4224	58.8950	112.2924						
Type	STD3	3	11	19	27	35						
Result	125.0000	1.7604	0.3414	0.8185	9.9487	0.6930						
OD value	0.7651	0.0579	0.0082	-0.0311	0.1141	0.0101						
Conc	125.0000	1.7604	0.3414	0.8185	9.9487	0.6930						
Type	STD4	4	12	20	28	36						
Result	62.5000	0.8653	0.5186	37.1574	1.0516	6.0545						
OD value	0.4789	-0.0186	-0.0148	0.2992	0.0076	0.0871						
Conc	62.5000	0.8653	0.5186	37.1574	1.0516	6.0545						
Type	STD5	5	13	21	29	37						
Result	31.2500	0.4385	1.3435	31.9589	4.2210	1.0979						
OD value	0.2854	-0.0306	-0.0236	0.2648	0.0745	0.0032						
Conc	31.2500	0.4385	1.3435	31.9589	4.2210	1.0979						
Type	STD6	6	14	22	30	38						
Result	15.6250	1.2670	0.9276	1.1441	2.9706	1.2670						
OD value	0.1269	-0.0124	0.0151	-0.0114	0.0660	0.0400						
Conc	15.6250	1.2670	0.9276	1.1441	2.9706	1.2670						
Type	STD7	7	15	23	31	39						
Result	7.8125	0.1763	1.0979	446.3895	0.9897	0.8497						
OD value	0.1077	0.0016	-0.0192	1.7670	-0.0077	0.0438						
Conc	7.8125	0.1763	1.0979	446.3895	0.9897	0.8497						
Type	BLK	8	16	24	32	40						
Result	0.0000	3.1185	1.2737	0.8965	0.5664	8.4949						
OD value	0.0000	0.0670	0.0547	0.0335	-0.0003	0.1040						
Conc	0.0000	3.1185	1.2737	0.8965	0.5664	8.4949						



Item:IL-6 BT Lab

Test Time : 18/09/2023 13:46:00



Optimized using
trial version
www.balesio.com

Lampiran 5. Informed consent tindakan dan kesediaan menjadi subjek penelitian

FORMULIR PERSETUJUAN
(INFORMED CONSENT)

Yang bertanda tangan di bawah ini:

Nama :
Umur :
Jenis Kelamin :
Alamat :
No. HP :

Setelah mendengar dan mengerti penjelasan dari peneliti maka dengan ini saya menyatakan bersedia secara sukarela tanpa paksaan untuk menjadi subjek penelitian.

**PERBANDINGAN KADAR *HEAT SHOCK PROTEIN* (HSP)-70
DAN INTERLEUKIN 6 PRE DAN POST OPERASI
PASIEIN RINOSINUSITIS KRONIK**

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini tanpa kehilangan hak saya untuk mendapatkan pelayanan kesehatan.

Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan saya dengan ini menyetujui semua data yang dihasilkan pada penelitian ini untuk dipublikasikan dalam bentuk lisan maupun tulisan.

Makassar, 2023

Nama Saksi

|

(.....)

(Nama jelas/Tanda tangan)

(.....)

(Nama jelas/Tanda tangan)



Lampiran 6. Surat Izin Etik Penelitian



REKOMENDASI PERSETUJUAN ETIK

Nomor : 454/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 4 Juli 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23030201		No Sponsor	
Peneliti Utama	dr. Michelia		Sponsor	
Judul Peneliti	Perbandingan Kadar Heat Shock Protein (HSP)-70 dan Interleukin 6 Pre dan Post Operasi Pasien Rinosinusitis Kronik			
No Versi Protokol	2	Tanggal Versi	13 Juni 2023	
No Versi PSP	2	Tanggal Versi	13 Juni 2023	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo dan RS Jejaring Makassar			
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal		Masa Berlaku 4 Juli 2023 sampai 4 Juli 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama	Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)		Tanda tangan
Sekretaris KEP Universitas Hasanuddin	Nama	dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		Tanda tangan

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



Optimized using
trial version
www.balesio.com


Lampiran 7.

Cara pengambilan sampel pada subjek penelitian



Optimized using
trial version
www.balesio.com

Cara Pengolahan sampel di Laboratorium HUMRC RSPTN UNHAS



Optimized using
trial version
www.balesio.com